Ampio's Ampion - Strong Positives With Clear Risks
- Data for Ampion's Phase 3 is due around July. Ampion is Ampio's albumin-based candidate for osteoarthritis treatment.
- The FDA has already made positive hints towards approval, calling the data already available "robust" and "sufficient".
- Despite these obvious positives, the risks are clear. Some positives may already be priced in, and other companies marketing new osteoarthritis treatments have had slow sales to start.
- The stock will jump higher assuming approval, but longer term it can go either way.